Table 4.
Prevalence of different severity levels of DR and macular oedema by diabetes status
| Newly diagnosed diabetes* (n=936) | Known Diabetes* (n=374) |
P value† | |||
| Patient number | Prevalence (%) (95% CI) | Patient number | Prevalence (%) (95% CI) | ||
| No DR | 832 | 88.9 (86.8 to 90.9) | 246 | 65.8 (61.0 to 70.6) | – |
| Any DR | 104 | 11.1 (9.1 to 13.2) | 129 | 34.5 (29.4 to 39.0) | <0.001 |
| DR grade | <0.001 | ||||
| Mild NPDR | 80 | 8.6 (6.8 to 10.4) | 59 | 15.8 (12.1 to 19.5) | – |
| Moderate NPDR | 17 | 1.8 (1.0 to 2.7) | 48 | 12.8 (9.4 to 16.2) | – |
| Severe NPDR | 6 | 0.6 (0.1 to 1.2) | 11 | 2.9 (1.2 to 4.7) | – |
| PDR | 1 | 0.1 (0 to 0.3) | 11 | 2.9 (1.0 to 4.3) | – |
| VTDR | 9 | 1.0 (0.3 to 1.6) | 24 | 6.4 (3.9 to 8.9) | <0.001 |
| DME | 9 | 1.0 (0.3 to 1.6) | 27 | 7.2 (4.6 to 9.8) | <0.001 |
| CSME | 3 | 0.3 (0 to 0.7) | 9 | 2.4 (0.8 to 4.0) | <0.001 |
*Of the 1,500 persons with type 2 DM, 1,310 had fundus photography results that were usable for DR grading.
†P value for the difference between newly diagnosed and known diabetic patients based on χ2 test.
CSME, clinically significant macular oedema; DME, diabetic macular oedema; DR, diabetic retinopathy; NPDR, non-proliferative diabetic retinopathy; PDR, proliferative diabetic retinopathy; VTDR, vision-threatening diabetic retinopathy.